Sector Expert: Punit Dhillon
Punit Dhillon is the cofounder and CEO of OncoSec Medical Inc., a biotechnology company developing its advanced-stage immunotherapy to treat solid tumors. He was formerly Vice President of Finance and Operations at Inovio Pharmaceuticals Inc. In his management experience, Mr. Dhillon has raised over $200 million through multiple financings and several licensing deals, including early-stage deals with Merck and Wyeth. His management experience spans corporate finance, M&A, integration, successful in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities, and working with several key opinion leaders worldwide. Mr. Dhillon is also the founder of BeCancerPositive.org, an online community where people can share their experiences with cancer and inspire hope for others. Mr. Dhillon holds a Bachelor of Arts with Honors in Political Science and a minor in Business Administration from Simon Fraser University.
Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment.